Session » 4M094 ACR/ARHP Abstract: Health Services Research I: Focus on Big Data (1887–1892)

Date: Monday, October 22, 2018

Time: 2:30PM-4:00PM

Meeting: 2018 ACR/ARHP Annual Meeting

Abstract Number: 1887

Practice Variation in Prescriptions of Non-TNFi Biologics and Tofacitinib: Data from the Rheumatology Informatics System for Effectiveness (RISE) Registry

Abstract Number: 1888

SLE Among the Leading Causes of Years of Potential Life Lost in Young Women: Population-Based Study, 2000-2015

Abstract Number: 1889

Patterns of Glucocorticoid Use and Provider-Level Variation in a Commercially Insured Incident Rheumatoid Arthritis Population

Abstract Number: 1890

Longitudinal Deep Learning on Electronic Health Record Data to Predict Future Rheumatoid Arthritis Disease Activity

Abstract Number: 1891

Patterns of Biosimilar Use in the Rheumatology Informatics System for Effectiveness (RISE) Registry

Abstract Number: 1892

Patient and Health System Characteristics Associated with Receipt of Disease Modifying Anti-Rheumatic Drugs in a National VA Sample

« View all sessions from this meeting

All abstracts accepted to ACR Convergence are under embargo once the ACR has notified presenters of their abstract’s acceptance, and cannot be presented at other meetings after this time. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until November 7 at 10:00 AM ET. Journalists with access to embargoed information also cannot release articles before this time.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Permissions and Reprints

For information about abstract permissions and reprints, see ACR Convergence permissions and reprint policies.